» Articles » PMID: 16741575

Intermittent Pressure Overload Triggers Hypertrophy-independent Cardiac Dysfunction and Vascular Rarefaction

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2006 Jun 3
PMID 16741575
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

For over a century, there has been intense debate as to the reason why some cardiac stresses are pathological and others are physiological. One long-standing theory is that physiological overloads such as exercise are intermittent, while pathological overloads such as hypertension are chronic. In this study, we hypothesized that the nature of the stress on the heart, rather than its duration, is the key determinant of the maladaptive phenotype. To test this, we applied intermittent pressure overload on the hearts of mice and tested the roles of duration and nature of the stress on the development of cardiac failure. Despite a mild hypertrophic response, preserved systolic function, and a favorable fetal gene expression profile, hearts exposed to intermittent pressure overload displayed pathological features. Importantly, intermittent pressure overload caused diastolic dysfunction, altered beta-adrenergic receptor (betaAR) function, and vascular rarefaction before the development of cardiac hypertrophy, which were largely normalized by preventing the recruitment of PI3K by betaAR kinase 1 to ligand-activated receptors. Thus stress-induced activation of pathogenic signaling pathways, not the duration of stress or the hypertrophic growth per se, is the molecular trigger of cardiac dysfunction.

Citing Articles

Regulatory effects of resveratrol on nitric oxide signaling in cardiovascular diseases.

Abolfazli S, Karav S, Johnston T, Sahebkar A Pharmacol Rep. 2025; .

PMID: 39832074 DOI: 10.1007/s43440-025-00694-w.


USP20 deletion promotes eccentric cardiac remodeling in response to pressure overload and increases mortality.

Jean-Charles P, Roy B, Yu S, Pironti G, Nagi K, Mao L Am J Physiol Heart Circ Physiol. 2024; 327(5):H1257-H1271.

PMID: 39365672 PMC: 11559650. DOI: 10.1152/ajpheart.00329.2024.


Isoproterenol induced cardiac hypertrophy: A comparison of three doses and two delivery methods in C57BL/6J mice.

Perez-Bonilla P, LaViolette B, Bhandary B, Ullas S, Chen X, Hirenallur-Shanthappa D PLoS One. 2024; 19(7):e0307467.

PMID: 39038017 PMC: 11262646. DOI: 10.1371/journal.pone.0307467.


TRPV4 Channels Promote Pathological, but Not Physiological, Cardiac Remodeling through the Activation of Calcineurin/NFAT and TRPC6.

Yanez-Bisbe L, Moya M, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Tajes M Int J Mol Sci. 2024; 25(3).

PMID: 38338818 PMC: 10855372. DOI: 10.3390/ijms25031541.


Treatment patterns and trajectories in patients after acute heart failure hospitalization.

Nakamaru R, Shiraishi Y, Kohno T, Nagatomo Y, Akiyama H, Motoya Y ESC Heart Fail. 2023; 11(2):692-701.

PMID: 38098210 PMC: 10966272. DOI: 10.1002/ehf2.14635.


References
1.
Levy D, Garrison R, Savage D, Kannel W, CASTELLI W . Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322(22):1561-6. DOI: 10.1056/NEJM199005313222203. View

2.
Rockman H, Ross R, Harris A, Knowlton K, Steinhelper M, Field L . Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991; 88(18):8277-81. PMC: 52490. DOI: 10.1073/pnas.88.18.8277. View

3.
Somers V, Dyken M, Clary M, Abboud F . Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 96(4):1897-904. PMC: 185826. DOI: 10.1172/JCI118235. View

4.
Choi D, Koch W, Hunter J, Rockman H . Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem. 1997; 272(27):17223-9. DOI: 10.1074/jbc.272.27.17223. View

5.
Lowes B, Minobe W, Abraham W, Rizeq M, Bohlmeyer T, QUAIFE R . Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997; 100(9):2315-24. PMC: 508428. DOI: 10.1172/JCI119770. View